Login to Your Account



PPL, Bayer Halt AAT Program; PPL Considering Cutting Staff

By Nuala Moran


Friday, June 20, 2003
LONDON - The prospect of a commercial return from the technology that produced Dolly the cloned sheep was put on hold Wednesday when Bayer Healthcare announced it was temporarily pulling the plug on the development of alpha-1-antitripsin, being developed in a $40 million collaboration with PPL Therapeutics plc. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription